I believe in finding the best, most cutting edge treatments to personalize care for my patients
Dr. Pollyea received his MD degree from the University of Chicago Pritzker School of Medicine. He stayed at the University of Chicago Hospital for his residency in Internal Medicine and served as Chief Medical Resident at Cook County Hospital. He then completed his fellowship training in Hematology and Oncology at Stanford University, where he also completed a Masters degree in Epidemiology with an emphasis on biostatistics and clinical trial design. In 2011 he came to the University of Colorado where he is currently the Clinical Director of Leukemia Services. Dr. Pollyea has served as the Principal Investigator of multiple early-phase clinical trials, and has received funding for his work from the American Society of Hematology, the American Society of Clinical Oncology and the Leukemia and Lymphoma Society. He has over 80 peer-reviewed publications and has spoken at many national and international meetings.
Qualifications and experience
- Hematology, Medical Oncology, Internal Medicine, Cancers, Blood / Lymphatic System, Cancers - Lymphoma, Cancers - Leukemia (Adult Chronic), Cancers - Leukemia (Adult Acute), Blood / Lymphatic System - Blood Disorders
- Languages spoken
Stanford University Program (2010)
University of Chicago Division of the Biological Sciences The Pritzker School of Medicine (2003)
John H Stroger Hospital of Cook County Program (2007)
University of Chicago Program (2006)
Indiana University–Bloomington (IN) (1999)
Stanford University (2011)
- Clinical interest for patients
I am interested in early phase clinical trials for patients with hematological malignancies. I believe in finding the best, most cutting edge treatments to personalize care for my patients.
University of Colorado Blood Cancer and BMT Program Website
- Research interest for patients
Dr. Pollyea’s research interests involve developmental therapeutics for myeloid malignancies (myelodysplastic syndromes and acute myeloid leukemia) through collaborative laboratory-based efforts and clinical trials involving novel therapies that he designs and leads. He is interested in developing drugs that target leukemia stem cells that will allow for definitive and curative therapies.